Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

This study is currently recruiting participants.

Verified by JANSSEN Alzheimer Immunotherapy Research & Development, LLC, December 2009

First Received: December 10, 2007 Last Updated: December 15, 2009 History of Changes

Sponsor:	JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Information provided by:	JANSSEN Alzheimer Immunotherapy Research & Development, LLC
ClinicalTrials.gov Identifier:	NCT00574132

Purpose

This is a multicenter, double-blind, placebo controlled, randomized, outpatient multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD. Approximately 230 study sites in the US and Canada and up to 35 sites outside of North America will be involved. Patients will be randomized to receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.

Bapineuzumab is a humanized monoclonal antibody, which binds to and clears beta amyloid peptide, and is designed to provide antibodies to beta amyloid directly to the patient.

Condition	Intervention	Phase
Alzheimer's Disease	Drug: Bapineuzumab Drug: Placebo Control	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment
Official Title:	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers.

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease

Drug Information available for: Bapineuzumab

U.S. FDA Resources

Further study details as provided by JANSSEN Alzheimer Immunotherapy Research & Development, LLC:

Primary Outcome Measures:

Cognitive and Functional [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Cognitive and Global [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Estimated Enrollment:	1250
Study Start Date:	December 2007
Estimated Primary Completion Date:	June 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Active Comparator	Drug: Bapineuzumab
B: Active Comparator	Drug: Bapineuzumab
C: Active Comparator	Drug: Bapineuzumab
D: Placebo Comparator	Drug: Placebo Control

Eligibility

Ages Eligible for Study:	50 Years to 88 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of probable AD
Age from 50 to less than 89
Mini-Mental Status Exam score of 16-26 inclusive
Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD
Stable doses of medications (cholinesterase inhibitors and memantine allowed)
Caregiver able to attend all clinic visits with patient

Exclusion Criteria:

Significant neurological disease other than AD
Major psychiatric disorder
Significant systemic illness
History of stroke or seizure, autoimmune disease, myocardial infarction within the last 2 years
Smoking greater than 20 cigarettes per day
Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications
Prior treatment experimental immunotherapeutics or vaccines for AD
Women of childbearing potential
Presence of pacemakers, CSF shunts, or foreign metal objects in the eyes, skin or body

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00574132

Contacts

Contact: Study Coordinator

1-866-446-5463

Show 239 Study Locations

Sponsors and Collaborators

JANSSEN Alzheimer Immunotherapy Research & Development, LLC

More Information

No publications provided

Responsible Party:	JANSSEN Alzheimer Immunotherapy Research & Development, LLC ( VP Clinical Development )
Study ID Numbers:	ELN115727-301
Study First Received:	December 10, 2007
Last Updated:	December 15, 2009
ClinicalTrials.gov Identifier:	NCT00574132 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Alzheimer Disease
Central Nervous System Diseases

Neurodegenerative Diseases
Tauopathies
Brain Diseases
Dementia

ClinicalTrials.gov processed this record on February 08, 2010